GlassScriptPhysician profile
Inderpal Singh Randhawa
NPI 1316035363
$1,712.30
in general payments reported to CMS, 2019-2025
16 companies · $73.62 in 2025
The $73.62 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $128 · 2021: $358 · 2022: $166 · 2023: $87.65 · 2024: $185 · 2025: $73.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $365.63 | 2019-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $337.08 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $308.93 | 2019-2024 | Wainua |
| Genentech USA, INC. | $184.53 | 2019-2021 | |
| Phadia US INC. | $107.91 | 2021-2024 | Immunocap |
| Genzyme Corporation | $86.33 | 2019-2022 | |
| Csl Behring | $71.44 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.57 | 2020-2021 | |
| Pfizer INC. | $47.33 | 2019-2020 | |
| Grifols USA, LLC | $27.48 | 2021 | |
| Bio Products Laboratory USA, INC. | $27.04 | 2019 | |
| Kaleo, INC. | $24.59 | 2019 | |
| Horizon Therapeutics Plc | $22.64 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $19.84 | 2019 | |
| Gilead Sciences, INC. | $17.00 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $16.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inderpal Randhawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.